MCID: PPT001
MIFTS: 41

Peptic Esophagitis

Categories: Gastrointestinal diseases

Aliases & Classifications for Peptic Esophagitis

MalaCards integrated aliases for Peptic Esophagitis:

Name: Peptic Esophagitis 12 15 73
Reflux Esophagitis 12 76
Gastro-Esophageal Reflux Disease with Esophagitis 73
Peptic Reflux Disease 12
Reflux Oesophagitis 12
Esophagitis, Peptic 44

Classifications:



External Ids:

Disease Ontology 12 DOID:13976
ICD9CM 35 530.11
MeSH 44 D004942

Summaries for Peptic Esophagitis

MalaCards based summary : Peptic Esophagitis, also known as reflux esophagitis, is related to duodenitis and hernia, hiatus. An important gene associated with Peptic Esophagitis is ATP12A (ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit), and among its related pathways/superpathways are Legionellosis and Interleukin-10 signaling. The drugs Dexlansoprazole and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include lymph node, spleen and testes.

Wikipedia : 76 Gastroesophageal reflux disease (GERD), also known as acid reflux, is a long-term condition where... more...

Related Diseases for Peptic Esophagitis

Diseases related to Peptic Esophagitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 114)
# Related Disease Score Top Affiliating Genes
1 duodenitis 31.1 ATP12A ATP4A
2 hernia, hiatus 29.9 ATP12A ATP4A CYP2C19 PAM
3 esophagitis 29.4 CXCL8 CYP2C19 HRH2 IL1B
4 duodenal ulcer 28.3 CXCL8 CYP2C19 HRH2 IL1B
5 gastroesophageal reflux 28.2 CXCL8 CYP2C19 HRH2 IL1B
6 peptic ulcer disease 28.0 ATP4A CXCL8 CYP2C19 HRH2 IL1B
7 gastric ulcer 28.0 CXCL8 CYP2C19 HRH2 IL1B
8 gastroparesis 11.3
9 barrett esophagus 11.1
10 duodenal atresia 11.0
11 fungal esophagitis 10.7 ATP12A ATP4A
12 bladder calculus 10.7 ATP12A ATP4A
13 gastrointestinal neuroendocrine benign tumor 10.7 ATP12A ATP4A
14 neonatal candidiasis 10.7 ATP12A ATP4A
15 photoallergic dermatitis 10.7 ATP12A ATP4A
16 squamous papillomatosis 10.7 ATP12A ATP4A
17 acute laryngitis 10.7 ATP12A ATP4A
18 gastroduodenal crohn's disease 10.7 ATP12A ATP4A
19 gastric neuroendocrine neoplasm 10.7 ATP12A ATP4A
20 toxic megacolon 10.7 ATP12A ATP4A
21 postsurgical hypothyroidism 10.7 ATP12A ATP4A
22 gastric antral vascular ectasia 10.7 ATP12A ATP4A
23 rumination disorder 10.7 ATP12A ATP4A
24 bile reflux 10.7 ATP12A ATP4A
25 granulomatous gastritis 10.7 ATP12A ATP4A
26 laryngeal disease 10.7 ATP12A ATP4A
27 ischemic neuropathy 10.7 ATP12A ATP4A
28 capillary disease 10.7 ATP12A ATP4A
29 duodenal disease 10.7 ATP12A ATP4A
30 dyskinesia of esophagus 10.7 ATP12A ATP4A
31 congenital disorder of deglycosylation 10.7 ATP12A ATP4A
32 anismus 10.7 ATP12A ATP4A
33 esophageal atresia/tracheoesophageal fistula 10.7 ATP12A ATP4A
34 laryngeal tuberculosis 10.7 ATP12A ATP4A
35 lymphocytic colitis 10.7 ATP12A ATP4A
36 lower urinary tract calculus 10.7 ATP12A ATP4A
37 aspiration pneumonia 10.7 ATP12A ATP4A
38 diarrhea 1, secretory chloride, congenital 10.7 ATP12A ATP4A
39 chronic intestinal vascular insufficiency 10.7 ATP12A ATP4A
40 eosinophilic gastritis 10.7 ATP12A ATP4A
41 polyposis, skin pigmentation, alopecia, and fingernail changes 10.7 ATP12A ATP4A
42 esophageal varix 10.7 ATP12A ATP4A
43 esophagus adenocarcinoma 10.7 ATP12A ATP4A
44 myopathy, x-linked, with excessive autophagy 10.7 ATP12A ATP4A
45 gastric lymphoma 10.7 ATP12A ATP4A
46 pancreatic steatorrhea 10.6 ATP12A ATP4A
47 pneumatosis cystoides intestinalis 10.6 ATP12A ATP4A
48 superior mesenteric artery syndrome 10.6 ATP12A ATP4A
49 lateral medullary syndrome 10.6 ATP12A ATP4A
50 cloacal exstrophy 10.6 ATP12A ATP4A

Comorbidity relations with Peptic Esophagitis via Phenotypic Disease Network (PDN): (show all 14)


Active Peptic Ulcer Disease Acute Cystitis
Anxiety Bronchitis
Chronic Myocardial Ischemia Deficiency Anemia
Esophageal Disease Esophagitis
Gastroesophageal Reflux Heart Disease
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Ischemic Heart Disease

Graphical network of the top 20 diseases related to Peptic Esophagitis:



Diseases related to Peptic Esophagitis

Symptoms & Phenotypes for Peptic Esophagitis

Drugs & Therapeutics for Peptic Esophagitis

Drugs for Peptic Esophagitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexlansoprazole Approved, Investigational Phase 4,Phase 2,Not Applicable 138530-94-6, 103577-45-3 9578005
2
Lansoprazole Approved, Investigational Phase 4,Phase 2,Not Applicable 103577-45-3 3883
3
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 73590-58-6 4594
4
Rabeprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 117976-89-3 5029
5
Domperidone Approved, Investigational, Vet_approved Phase 4 57808-66-9 3151
6
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
7
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 161796-78-7, 119141-88-7 4594 9579578
8
Trimebutine Approved Phase 4 39133-31-8
9 Rebamipide Investigational Phase 4 90098-04-7
10
Maleic acid Experimental Phase 4 110-16-7 444266
11 Antacids Phase 4,Phase 3,Phase 2,Phase 1
12 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Proton Pump Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
17 Omeprazole, sodium bicarbonate drug combination Phase 4
18 Antioxidants Phase 4
19 Protective Agents Phase 4
20 Antiemetics Phase 4
21 Autonomic Agents Phase 4
22 Dopamine Agents Phase 4
23 Dopamine Antagonists Phase 4
24 Pepsin A Phase 4
25 Parasympatholytics Phase 4
26
Famotidine Approved Phase 3 76824-35-6 3325
27
Histamine Approved, Investigational Phase 3,Phase 1 75614-87-8, 51-45-6 774
28
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
29
Menthol Approved Phase 3,Not Applicable 2216-51-5 16666
30
Lafutidine Investigational Phase 3 118288-08-7 5282136
31 Analgesics Phase 3,Phase 1,Phase 2
32 Analgesics, Non-Narcotic Phase 3,Phase 1,Phase 2
33 Anti-Inflammatory Agents Phase 3,Phase 1,Phase 2
34 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 1,Phase 2
35 Antirheumatic Agents Phase 3,Phase 1,Phase 2
36 Cyclooxygenase Inhibitors Phase 3,Phase 1,Phase 2
37 Histamine Antagonists Phase 3,Phase 1
38 Histamine H2 Antagonists Phase 3,Phase 1
39
Histamine Phosphate Phase 3,Phase 1 51-74-1 65513
40 Antipyretics Phase 3
41 Fibrinolytic Agents Phase 3
42 Platelet Aggregation Inhibitors Phase 3
43 lanreotide Approved Phase 2 108736-35-2
44
Somatostatin Approved, Investigational Phase 2 38916-34-6, 51110-01-1 53481605
45
Lornoxicam Approved, Investigational Phase 1, Phase 2 70374-39-9 5282204
46
Morphine Approved, Investigational Phase 1, Phase 2 57-27-2 5288826
47
Piroxicam Approved, Investigational Phase 1, Phase 2 36322-90-4 5280452 54676228
48
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
49
Imidacloprid Vet_approved Phase 2 105827-78-9 86418
50 Angiopeptin Phase 2

Interventional clinical trials:

(show top 50) (show all 91)
# Name Status NCT ID Phase Drugs
1 Treatment Effect Between Dexlansoprazole and Double-dose Lansoprazole in Obesity Patients With Reflux Esophagitis Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
2 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
3 An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis Completed NCT01008696 Phase 4 Rabeprazole;Lansoprazole
4 Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation Completed NCT03116841 Phase 4 Vonoprazan
5 The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD Completed NCT01860482 Phase 4 Newrabell® Tablet 10mg
6 Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study Completed NCT00693225 Phase 4 Omeprazole/sodium bicarbonate
7 A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis Completed NCT02755753 Phase 4 Lansoprazole;Rebamipide;Rebamipide-placebo
8 Role of Pepsin Assay in Wheezy Infants Completed NCT02685436 Phase 4 Omeprazole and domperidone
9 To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole Completed NCT01397084 Phase 4 esomeprazole 20 mg
10 NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis Completed NCT00206180 Phase 4 esomeprazole magnesium (oral medication)
11 Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Recruiting NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
12 Transoral Incisionless Fundoplication (TIF) Versus Sham for Treatment of Gastroesophageal Reflux Disease (GERD) Active, not recruiting NCT01110811 Phase 4
13 Efficacy of Zinc L-carnosine in Maintaining Remission of Gastroesophageal Reflux Disease Not yet recruiting NCT03467438 Phase 4 Zinc-l-carnosine
14 A Trial of Reconstruction After Distal Gastrectomy for Gastric Cancer Unknown status NCT01065688 Phase 3
15 Laparoscopic Repair of Giant Hiatal Hernias With Nitinol-framed Lightweight Polytetrafluoroethylene Mesh Unknown status NCT01780285 Phase 3
16 Laparoscopic Lightweight Mesh Repair of Large Hiatal Hernias Unknown status NCT01408108 Phase 3
17 Reflux Esophagitis Phase III Study (Maintenance Treatment) Completed NCT00634114 Phase 3 Esomeprazole;Esomeprazole;Omeprazole
18 Reflux Esophagitis Phase III Study (Initial Treatment) Completed NCT00633932 Phase 3 Esomeprazole;Esomeprazole;Omeprazole
19 Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus) Completed NCT01669811 Phase 3 Esomeprazole (D961H) twice daily;Esomeprazole (D961H) once daily
20 Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis Completed NCT00770913 Phase 2, Phase 3 E3810;E3810;E3810
21 Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine - Completed NCT00229424 Phase 3 Lafutidine;Famotidine
22 Sopran - Omeprazole Treatment Versus Surgery Completed NCT00256737 Phase 3 Omeprazole
23 A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases Completed NCT02153398 Phase 3 D961H sachet 10 mg;D961H capsule 10mg;D961H capsule 20 mg
24 Phase III General Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy Completed NCT00745459 Phase 3 NPO-11
25 Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin Completed NCT01069939 Phase 3 Esomeprazole;Placebo
26 A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer Not yet recruiting NCT03553563 Phase 3 D961H capsule 10mg;D961H sachet 10mg
27 Laparoscopy-assisted Proximal Gastrectomy Versus and Laparoscopy-assisted Total Gastrectomy Terminated NCT01433861 Phase 3
28 Comparison Study for Bile Reflux and Gastric Stasis in Patients After Distal Gastrectomy Withdrawn NCT00622804 Phase 3
29 Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy Unknown status NCT02054637 Phase 2 Lanreotide
30 The Advantages and Disadvantages Between Uncut Roux-en-Y Reconstruction and Billroth II Reconstruction After Laparoscopy-assisted Distal Gastrectomy for Gastric Unknown status NCT02694081 Phase 2
31 Continuous Lornoxicam Infusion for Orthopaedic Surgery Unknown status NCT01718756 Phase 1, Phase 2 Placebo;Continuous infusion;Scheduled
32 Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis Completed NCT01538849 Phase 2 Esomeprazole 40mg;YH4808 A mg;YH4808 B mg;YH4808 C mg
33 Pharmacokinetics of Enteral Omeprazole Suspension in Patients With Cerebral Palsy and Mental Retardation Completed NCT00426595 Phase 2 Administration of omeprazole suspension;omeprazole administered as a multi-unit-pellet system
34 Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer Active, not recruiting NCT02845986 Phase 2 oxaliplatin
35 Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection Enrolling by invitation NCT03050879 Phase 2 Indocyanine Green Tracer
36 Randomized Controlled Trials on Clinical Outcomes of Totally Laparoscopic Versus Laparoscopy Assisted Total Gastrectomy for Gastric Cancer Enrolling by invitation NCT03006263 Phase 2
37 A Phase 2 Study of Dexlansoprazole Delayed-Release Capsules to Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Pediatric Subjects Aged 1 to 11 Years Suspended NCT02616302 Phase 2 Dexlansoprazole
38 Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD Withdrawn NCT01025739 Phase 2
39 Effect of Repeated Doses of YF476, Omeprazole and Placebo on Stomach Acidity in Healthy Volunteers Completed NCT01599858 Phase 1 YF476;Omeprazole
40 Effect of 5, 10 or 25 mg of YF476 Daily for 14 Days on Stomach Acidity in Healthy Volunteers Completed NCT01597674 Phase 1 YF476
41 Effect of Single Doses of YF476 on Stomach Acidity Compared With Ranitidine and Placebo in Fasted and Fed States Completed NCT01538797 Phase 1 YF476;Ranitidine
42 Safety, Tolerability and Pharmacokinetics of Single Rising Doses of YF476, a Gastrin Antagonist, in Healthy Men Completed NCT01538784 Phase 1 YF476
43 BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects Completed NCT01964131 Phase 1 D961H sachet 20 mg;D961H HPMC capsule 20 mg
44 Incidence of Reflux Esophagitis After Pancreaticoduodenectomy Unknown status NCT01311908
45 Adipokines and the Risk of Reflux Esophagitis Unknown status NCT01560598
46 Immunologic Factors in Reflux Esophagitis and Barrett’s Esophagus Unknown status NCT00155805
47 24 Hour Esophageal and Electrogastrography to Investigate the Mechanism of Reflux Esophagitis Unknown status NCT00154570
48 The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients Unknown status NCT02149914 Not Applicable PPI
49 Oxidative Stress in Intestinal Metaplasia and Metabolic Syndrome Unknown status NCT02695186
50 Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis Completed NCT01321567 rabeprazole sodium

Search NIH Clinical Center for Peptic Esophagitis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: esophagitis, peptic

Genetic Tests for Peptic Esophagitis

Anatomical Context for Peptic Esophagitis

MalaCards organs/tissues related to Peptic Esophagitis:

41
Lymph Node, Spleen, Testes

Publications for Peptic Esophagitis

Articles related to Peptic Esophagitis:

(show top 50) (show all 93)
# Title Authors Year
1
Turning the Pathogenesis of Acute Peptic Esophagitis Inside Out. ( 27187299 )
2016
2
High rate of clinical and endoscopic relapse after healing of erosive peptic esophagitis in children and adolescents. ( 25023576 )
2014
3
The elucidation of peptic esophagitis: from Hamperl to heartburn. ( 18027318 )
2007
4
Omeprazole in infants with cimetidine-resistant peptic esophagitis. ( 9506656 )
1998
5
Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. ( 9226527 )
1997
6
A randomized blinded comparison of omeprazole and ranitidine in the treatment of chronic esophageal stricture secondary to acid peptic esophagitis. ( 8857137 )
1996
7
Omeprazole treatment of children with peptic esophagitis refractory to ranitidine therapy. ( 7858685 )
1995
8
Cimetidine in children with peptic esophagitis. ( 17586987 )
1992
9
Reply: Cimetidine in children with peptic esophagitis. ( 17586986 )
1992
10
Sucralfate used as adjunctive therapy in patients with severe erosive peptic esophagitis resulting from gastroesophageal reflux. ( 2220725 )
1990
11
Healing and relapse of severe peptic esophagitis after treatment with omeprazole. ( 3044912 )
1988
12
Sucralfate versus alginate/antacid in the treatment of peptic esophagitis. ( 2821808 )
1987
13
The surgical treatment of complicated peptic esophagitis. ( 3631761 )
1987
14
Esophageal peristaltic dysfunction in peptic esophagitis. ( 3743966 )
1986
15
Esophageal motor abnormalities in children with gastroesophageal reflux and peptic esophagitis. ( 3712155 )
1986
16
Pharyngoesophageal transmucosal potential difference in normal subjects and in patients with peptic esophagitis. ( 3557931 )
1986
17
Sucralfate prevents experimental peptic esophagitis in rabbits. ( 3917956 )
1985
18
The prevalence of Barrett's esophagus in patients with chronic peptic esophageal strictures. ( 6884161 )
1983
19
Esophagopericardial fistula in a scleroderma patient with peptic esophagitis. ( 6870424 )
1983
20
The child with peptic esophagitis: a correlation of radiologic signs with esophageal pathology. ( 7146395 )
1982
21
Surgical treatment of reflux peptic esophagitis. ( 7158861 )
1982
22
Surgical considerations in reflux peptic esophagitis. ( 721020 )
1978
23
Squamous cell papilloma of the esophagus. Report of a case after peptic esophagitis and repeated bougienage with review of the literature. ( 640347 )
1978
24
Nissen fundoplication for reflux peptic esophagitis. ( 871221 )
1977
25
Sliding esophageal hiatal hernia and reflux peptic esophagitis. ( 1099346 )
1975
26
Sliding esophageal hiatus hernia and reflux peptic esophagitis. ( 4477654 )
1974
27
Peptic esophagitis in a dog. ( 4744453 )
1973
28
Conservative operations for peptic esophagitis with stenosis in columnar-lined lower esophagus. ( 5037826 )
1972
29
Severe peptic esophagitis in a patient with Zollinger-Ellison syndrome. ( 5098624 )
1971
30
Comparison of crural repair and Nissen fundoplication in the treatment of esophageal hiatus hernia with peptic esophagitis. ( 5091580 )
1971
31
Chalasia, peptic esophagitis, and hiatal hernia. A common syndrome in patients with central nervous system disease. ( 5119882 )
1971
32
Hiatus hernia, duodenal ulcer and peptic esophagitis. ( 5766113 )
1969
33
Stenosing non-peptic esophagitis. ( 5377467 )
1969
34
The neglected hiatus hernia. Late complications of peptic esophagitis: esophageal stenosis and shortening. ( 5821710 )
1969
35
Mild gastric fundal irradiation in the treatment of peptic esophagitis. ( 5652789 )
1968
36
Alterations in motility of the esophagus in peptic esophagitis. ( 5640142 )
1968
37
Peptic esophagitis, hiatal hernia, and duodenal ulcer. A unified concept. ( 6021435 )
1967
38
Problems in the early diagnosis of peptic esophagitis. ( 6037461 )
1967
39
Anatomic etiology and operative treatment of peptic esophagitis: an experimental study. ( 6023932 )
1967
40
Treatment of hiatus hernia and peptic esophagitis through abdominal approach. ( 5906827 )
1966
41
Esophageal stenosis caused by peptic esophagitis or ulceration. ( 5325412 )
1966
42
An evaluation of surgery for hiatal hernia and peptic esophagitis. ( 5827234 )
1965
43
TREATMENT OF PEPTIC ESOPHAGITIS. ( 14221297 )
1964
44
PEPTIC ESOPHAGITIS. ITS SURGICAL SIGNIFICANCE. ( 14229738 )
1964
45
PEPTIC ESOPHAGITIS. ( 14132467 )
1964
46
HIATAL HERNIA AND PEPTIC ESOPHAGITIS. ( 14070804 )
1963
47
Current status of surgery for esophageal hiatal hernia, peptic esophagitis, and inflammatory stricture. ( 14014620 )
1963
48
Peptic esophagitis with stricture treated by reconstruction of the esophagus with a reversed gastric tube. ( 13906040 )
1962
49
Surgical treatment of peptic esophagitis. ( 15445917 )
1962
50
Peptic esophagitis. ( 13903957 )
1962

Variations for Peptic Esophagitis

Expression for Peptic Esophagitis

Search GEO for disease gene expression data for Peptic Esophagitis.

Pathways for Peptic Esophagitis

Pathways related to Peptic Esophagitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.06 CXCL8 IL1B
2 10.95 CXCL8 IL1B
3 10.85 CXCL8 IL1B
4 10.62 ATP4A HRH2
5 9.32 ATP4A HRH2

GO Terms for Peptic Esophagitis

Biological processes related to Peptic Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 potassium ion import GO:0010107 9.37 ATP12A ATP4A
2 ATP hydrolysis coupled proton transport GO:0015991 9.32 ATP12A ATP4A
3 cellular sodium ion homeostasis GO:0006883 9.26 ATP12A ATP4A
4 cellular potassium ion homeostasis GO:0030007 9.16 ATP12A ATP4A
5 sodium ion export across plasma membrane GO:0036376 8.96 ATP12A ATP4A
6 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 8.62 ATP12A ATP4A

Molecular functions related to Peptic Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 monooxygenase activity GO:0004497 9.16 CYP2C19 PAM
2 sodium:potassium-exchanging ATPase activity GO:0005391 8.96 ATP12A ATP4A
3 potassium:proton exchanging ATPase activity GO:0008900 8.62 ATP12A ATP4A

Sources for Peptic Esophagitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....